SCHEMBL4966955

SCHEMBL4966955

CN(CCc1ccccc1)C(=O)N1CC(C(=O)O)CC(c2ccccc2)C1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.51
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
FAAH O00519 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C1 Q04828 1/20 0.43
POLB P06746 2/20 0.41
S1PR1 P21453 1/20 0.41
S1PR5 Q9H228 1/20 0.41
LIPE Q05469 1/20 0.41
AGTR2 P50052 1/20 0.40
USP30 Q70CQ3 1/20 0.40
GAA P10253 1/20 0.40
F2R P25116 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL640841 0.79 F2R (0.48) HRH3ALDH1A1NPC1RAB9AS1PR1
SCHEMBL31435474 0.76 AKR1C3 (0.57) ALDH1A1NPC1HPGDRAB9AAKR1C3
SCHEMBL12719985 0.76 S1PR5 (0.41) HRH3RAB9APOLBS1PR1S1PR5
SCHEMBL23932469 0.70 AKR1C3 (0.57) NPC1RAB9AAKR1C3AKR1C1
SCHEMBL156662 0.70 RORC (0.51) AKR1C3AKR1C1USP30
SCHEMBL27266752 0.70 AKR1C3 (0.47) ALDH1A1AKR1C3AKR1C1POLBUSP30
SCHEMBL924621 0.70 GRIN2B (0.61) ALDH1A1NPC1AKR1C3AKR1C1
SCHEMBL662123 0.70 F2R (0.69) NPC1HPGDRAB9AFAAHPOLB
SCHEMBL4966951 0.70 RAB9A (0.48) HRH3ALDH1A1NPC1CYP3A4CYP2D6
SCHEMBL3723289 0.68 F2R (0.46) ALDH1A1AKR1C3AKR1C1POLBS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1954693-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2008-08-13 EP disclosed
WO-2007062007-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2007-05-31 WO disclosed